Experimental drug works on migraines
In Boston, an experimental drug sumatriptan shows rapid relief for most migraine sufferers. In a 639-patient study, injections reduced or eliminated pain within two hours, with about 90 percent relief versus 33 percent on placebo. The drug, from Glaxo Inc, is not FDA approved yet.
MENTIONED IN THIS ARTICLE
Boston
Glaxo Inc
US Food and Drug Administration
Michel D. Ferrari
University Hospital
Leiden
Netherlands
Canada
Israel
South Africa
FDA panel warned on breast implant risks and need for informed consent
FDA chief Dr. David Kessler urged doctors to fully disclose risks of silicon breast implants, as experts weigh potential cancer danger from polyurethane coated Mem e and Replicon devices. Bristol-Myers Squibb contends implants show no cancer risk. FDA may require safety proof or sales halt next year.
MENTIONED IN THIS ARTICLE
Gaithersburg
Food and Drug Administration
David A. Kessler
FDA
Surgitek
Bristol-Myers Squibb Co
TDA
Kessler
Gery
Sybil Niden Goldrich
Beverly Hills
Calif
Breast Implant Information Network
Teresa di Angelo
National Institutes of Health
Ms. di Angelo
Also Mentioned on This Page
Wickes Lumber
Timberline
Paint & Interior Products
All Krebs
Olympic
Formby’s
Teheestramatch
Wickes
Urbana Pike
Frederick PH
Frederick
Newspr